• +1-646-491-9876
    • +91-20-67278686

    Search

    Transforming Growth Factor Beta 1-Pipeline Review H1 2017

    Transforming Growth Factor Beta 1-Pipeline Review H1 2017

    • Report Code ID: RW0001834339
    • Category Pharmaceuticals
    • No. of Pages 65
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H1 2017

    Summary

    Transforming Growth Factor Beta 1 (TGFB1) - Transforming growth factor beta 1 (TGF-β1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. It promotes either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. It leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression at high concentration. It leads to expression of the IL-17 and IL-23 receptors favoring differentiation to Th17 cells at low concentration.

    Transforming Growth Factor Beta 1 (TGFB1) pipeline Target constitutes close to 16 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Ophthalmology, Cardiovascular, Central Nervous System, Genetic Disorders and Respiratory which include indications Fibrosis, Kidney Fibrosis, Liver Fibrosis, Acute Pain, Atherosclerosis, Autoimmune Disorders, Bile Duct Cancer (Cholangiocarcinoma) , Chronic Pancreatitis Pain, Glioblastoma Multiforme (GBM) , Head And Neck Cancer, Hypertrophic Scars, Inflammation, Metastatic Breast Cancer, Myelofibrosis, Non-Small Cell Lung Cancer, Open-Angle Glaucoma, Osteoarthritis, Osteogenesis Imperfecta, Proliferative Vitreoretinopathy (PVR) , Pulmonary Fibrosis, Scar, Skin Inflammation, Solid Tumor and Squamous Cell Carcinoma.

    The latest report Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H1 2017, outlays comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)
    - The report reviews Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 1 (TGFB1)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 1 (TGFB1) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Transforming Growth Factor Beta 1 (TGFB1) - Overview
    Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Transforming Growth Factor Beta 1 (TGFB1) - Companies Involved in Therapeutics Development
    Acceleron Pharma Inc
    Eli Lilly and Company
    Genzyme Corp
    Huabo Biopharm Co Ltd
    Isarna Therapeutics GmbH
    Johnson & Johnson
    Novartis AG
    Scholar Rock Inc
    Sirnaomics Inc
    Transforming Growth Factor Beta 1 (TGFB1) - Drug Profiles
    ACE-1332 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Antibody to Inhibit TGF-Beta 1 for Osteoarthritis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    decorin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fresolimumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HB-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ISTH-1047 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ISTH-1106 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    melittin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies to Inhibit TGF Beta 1 for Fibrosis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies to Inhibit TGF Beta1 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Activate TGF beta1 for Autoimmune Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit TGF-Beta 1 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Peptides to Inhibit TGF Beta 1 for Squamous Cell Carcinoma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    STP-705 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sulodexide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    XOMA-089 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Transforming Growth Factor Beta 1 (TGFB1) - Dormant Products
    Transforming Growth Factor Beta 1 (TGFB1) - Discontinued Products
    Transforming Growth Factor Beta 1 (TGFB1) - Product Development Milestones
    Featured News & Press Releases
    May 01, 2017: Sirnaomics Received IND Approval from CFDA for Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar
    Feb 06, 2017: Sirnaomics Initiates a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar
    Nov 07, 2016: Sirnaomics Received Green Light from US FDA for a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar
    Jul 14, 2015: Scholar Rock Presents Preclinical Data for First Demonstration of Novel Pharmacological Approach to Targeting the TGFß1 Latent Complex
    Jan 22, 2015: Sirnaomics Files to Begin Trial of Scar-healing Drug in China as it Seeks Funding in US
    Jan 05, 2015: Sirnaomics and Partner Submit IND to CFDA
    Jun 28, 2012: Sirnaomics Nears Phase I Study of Wound-Healing Drug as It Eyes the microRNA Field
    Jun 25, 2012: Sirnaomics Receives NIH SBIR Grant For Developing siRNA Therapeutic Product STP705
    Mar 27, 2008: Keryx Biopharmaceuticals Announces Termination Of SUN-MACRO Phase 4 Trial
    Mar 07, 2008: Keryx Biopharmaceuticals Announces That SUN-MICRO Phase 3 Clinical Trial Fails To Meet Primary Efficacy Endpoint
    Feb 11, 2008: Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
    Nov 14, 2007: Keryx Announces Positive Final Results From Phase 2 Clinical Study For KRX-101 (Sulodexide Gelcaps) For The Treatment Of Diabetic Nephropathy
    Oct 24, 2007: Keryx Biopharmaceuticals, Inc, Announces Final Phase II Data Presentation On KRX-101 At The Upcoming American Society Of Nephrology Renal Week
    Jun 29, 2007: Keryx Biopharmaceuticals, Inc. Initiates Pivotal Phase 3 And Phase 4 Clinical Program Of KRX-101 For Treatment Of Diabetic Nephropathy
    May 06, 2007: Keryx Announces Positive Interim Results From Phase 2 Clinical Study For KRX-101 (Sulodexide Gelcaps) For Treatment Of Diabetic Nephropathy
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Acceleron Pharma Inc, H1 2017
    Pipeline by Eli Lilly and Company, H1 2017
    Pipeline by Genzyme Corp, H1 2017
    Pipeline by Huabo Biopharm Co Ltd, H1 2017
    Pipeline by Isarna Therapeutics GmbH, H1 2017
    Pipeline by Johnson & Johnson, H1 2017
    Pipeline by Novartis AG, H1 2017
    Pipeline by Scholar Rock Inc, H1 2017
    Pipeline by Sirnaomics Inc, H1 2017
    Dormant Products, H1 2017
    Dormant Products, H1 2017 (Contd..1) , H1 2017
    Dormant Products, H1 2017 (Contd..2) , H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Acceleron Pharma Inc
    Eli Lilly and Company
    Genzyme Corp
    Huabo Biopharm Co Ltd
    Isarna Therapeutics GmbH
    Johnson & Johnson
    Novartis AG
    Scholar Rock Inc
    Sirnaomics Inc

    Request for Sample

    Report Url https://www.reportsweb.com//transforming-growth-factor-beta-1-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//transforming-growth-factor-beta-1-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//transforming-growth-factor-beta-1-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments